RAS野生型转移性结直肠癌患者FOLFOX联合抗EGFR诱导治疗后的最佳维持策略:随机临床试验的个体患者数据汇总分析
该汇总分析纳入四项随机II期试验的518例RAS野生型转移性结直肠癌患者,比较5-FU/LV、抗EGFR或两者联合维持治疗的疗效与毒性。联合维持组中位无进展生存期9.0个月优于单药组,总生存期无显著差异,但联合组不良事件增加。作者认为5-FU/LV联合抗EGFR是首选维持方案。
要点
- 联合维持组中位PFS为9.0个月,优于5-FU/LV组的5.6个月和抗EGFR组的6.0个月(P=0.009)。
- 单药维持(5-FU/LV或抗EGFR)较联合维持的PFS更差(HR 1.26,P=0.016)。
- 联合维持组总体任何级别及≥3级不良事件和特定不良事件较单药组增加。
核心结论
- 这项纳入四项随机II期试验的汇总分析支持将5-FU/LV联合抗EGFR作为首选的维持治疗方案。
- 数据为基于肿瘤和患者特征的更个体化维持治疗策略提供了依据。
研究设计与样本
- 本研究为个体患者数据汇总分析,纳入Valentino、Panama、MACRO-2、COIN-B四项随机临床试验。
- 纳入RAS野生型转移性结直肠癌患者,均接受FOLFOX联合帕尼单抗或西妥昔单抗一线治疗后按预定维持策略治疗。
- 仅纳入按分配组别开始维持治疗的患者,共518例。
- 按维持治疗类型分为5-FU/LV组(123例)、抗EGFR组(185例)和5-FU/LV联合抗EGFR组(210例)。
- 无进展生存期和总生存期自维持治疗开始计算,毒性评估限于维持治疗期间。
主要发现
- 5-FU/LV组、抗EGFR组和5-FU/LV联合抗EGFR组的中位无进展生存期分别为5.6、6.0和9.0个月(P=0.009)。
- 5-FU/LV组、抗EGFR组和5-FU/LV联合抗EGFR组的中位总生存期分别为25.7、24.0和28.0个月(P=0.134)。
- 单药维持(5-FU/LV或抗EGFR)较联合维持的无进展生存期更差(HR 1.26,P=0.016)。
- 单药维持较联合维持的总生存期呈非显著趋势(HR 1.20,P=0.111)。
- 联合维持组较5-FU/LV组或抗EGFR组总体任何级别不良事件、≥3级不良事件及特定不良事件增加。
临床怎么用
- 作者认为,基于该汇总分析,5-FU/LV联合抗EGFR可作为首选的维持治疗方案。
- 作者认为,数据为基于肿瘤和患者特征的更个体化维持治疗策略提供了依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-EGFR antibodies plus doublet chemotherapy is the standard of care in RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No phase-3 level of evidence is available to guide treatment de-escalation after anti-EGFR-based first-line. Several randomised clinical trials investigated de-intensification strategies with 5-fluorouracil/leucovorin (5-FU/LV) and/or anti-EGFR. METHODS: We performed an individual patient data pooled analysis of Valentino, Panama, MACRO-2, COIN-B trials including RAS wild-type mCRC patients who received first-line therapy with FOLFOX plus panitumumab or cetuximab followed by pre-specified maintenance strategy. Only patients who started maintenance according to the assigned arm were included. Patients were categorised by type of maintenance (i.e. 5-FU/LV, anti-EGFR or 5-FU/LV + anti-EGFR). Progression-free survival (PFS) and overall survival (OS) were calculated from the start of maintenance; toxicity was evaluated for the maintenance treatment period. RESULTS: A total of 518 patients were included in the pooled analysis. Overall, 123, 185 and 210 patients received maintenance with 5-FU/LV, anti-EGFR, 5-FU/LV + anti-EGFR, respectively. Median PFS was 5.6, 6.0 and 9.0 (P = 0.009) and OS was 25.7, 24.0 and 28.0 months (P = 0.134) in 5-FU/LV, anti-EGFR and 5-FU/LV + anti-EGFR arms, respectively. Monotherapy maintenance (either 5-FU/LV or anti-EGFR) was inferior to combination in terms of PFS (hazard ratios [HR] 1.26, P = 0.016) and non-significantly trending also in OS (HR 1.20, P = 0.111). An increase of overall any grade and grade ≥ 3 AEs and selected AEs was reported in combination compared to either 5-FU/LV or anti-EGFR arms. CONCLUSIONS: This pooled analysis including four randomised phase II supports the use of 5-FU/LV plus anti-EGFR as the preferred maintenance regimen. Data provide rational for a more individualised maintenance treatment approach based on tumour and patients features.
引用
- Raimondi A, Nichetti F, Stahler A, et al. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. Eur J Cancer. 2023. PMID: 37441940. doi:10.1016/j.ejca.2023.112945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。